{
    "clinical_study": {
        "@rank": "238",
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on April 14, 2020",
            "link_text": "Link to the current ClinicalTrials.gov record.",
            "url": "https://clinicaltrials.gov/show/NCT04310228"
        },
        "id_info": {
            "org_study_id": "2020YFC0844100",
            "nct_id": "NCT04310228"
        },
        "brief_title": "Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019",
        "official_title": "Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019-A Multicenter, Randomized and Controlled Clinical Trial Study",
        "sponsors": {
            "lead_sponsor": {
                "agency": "Peking University First Hospital",
                "agency_class": "Other"
            }
        },
        "source": "Peking University First Hospital",
        "oversight_info": {
            "is_fda_regulated_drug": "No",
            "is_fda_regulated_device": "No"
        },
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the efficacy and safety of favipiravir combined with\n      tocilizumab in the treatment of corona virus disease 2019."
        },
        "detailed_description": {
            "textblock": "In clinical institutions that enroll patients with corona virus disease 2019, three arms,\n      multi-center, randomized and controlled methods are adopted. Patients are divided into three\n      groups, favipiravir combined with tocilizumab group, favipiravir group and tocilizumab group.\n      150 patients are expected to be enrolled and the cases are allocated according to the ratio\n      of 3( favipiravir combined with tocilizumab group): 1(favipiravir group): 1(tocilizumab\n      group)."
        },
        "overall_status": "Recruiting",
        "start_date": {
            "@type": "Actual",
            "#text": "March 8, 2020"
        },
        "completion_date": {
            "@type": "Anticipated",
            "#text": "May 2020"
        },
        "primary_completion_date": {
            "@type": "Anticipated",
            "#text": "May 2020"
        },
        "phase": "N/A",
        "study_type": "Interventional",
        "has_expanded_access": "No",
        "study_design_info": {
            "allocation": "Randomized",
            "intervention_model": "Parallel Assignment",
            "primary_purpose": "Treatment",
            "masking": "None (Open Label)"
        },
        "primary_outcome": {
            "measure": "Clinical cure rate",
            "time_frame": "3 months",
            "description": "Definition of clinical cure: The viral load of the respiratory specimen was negative for two consecutive times (the interval between the two tests was greater than or equal to one day), the lung image improved, and the body temperature returned to normal for more than 3 days, and the clinical manifestation improved."
        },
        "secondary_outcome": [
            {
                "measure": "Viral nucleic acid test negative conversion rate and days from positive to negative",
                "time_frame": "14 days after taking medicine"
            },
            {
                "measure": "Duration of fever",
                "time_frame": "14 days after taking medicine"
            },
            {
                "measure": "Lung imaging improvement time",
                "time_frame": "14 days after taking medicine"
            },
            {
                "measure": "Mortality rate because of Corona Virus Disease 2019",
                "time_frame": "3 months"
            },
            {
                "measure": "Rate of non-invasive or invasive mechanical ventilation when respiratory failure occurs",
                "time_frame": "3 months"
            },
            {
                "measure": "Mean in-hospital time",
                "time_frame": "3 months"
            }
        ],
        "number_of_arms": "3",
        "enrollment": {
            "@type": "Anticipated",
            "#text": "150"
        },
        "condition": "COVID-19",
        "arm_group": [
            {
                "arm_group_label": "Favipiravir Combined With Tocilizumab group",
                "arm_group_type": "Experimental",
                "description": "Favipiravir: On the 1st day, 1600mg each time, twice a day; from the 2nd to the 7th day, 600mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days.\nTocilizumab:The first dose is 4 ~ 8mg/kg and the recommended dose is 400mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hours after the first dose and the interval between two medications \u2265 12 hours.Intravenous infusion, The maximum of cumulative number is two, and the maximum single dose does not exceed 800mg."
            },
            {
                "arm_group_label": "Favipiravir group",
                "arm_group_type": "Active Comparator",
                "description": "On the 1st day, 1600mg each time, twice a day; from the 2nd to the 7th day, 600mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days."
            },
            {
                "arm_group_label": "Tocilizumab group",
                "arm_group_type": "Active Comparator",
                "description": "The first dose is 4 ~ 8mg/kg and the recommended dose is 400mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hours after the first dose and the interval between two medications \u2265 12 hours.Intravenous infusion, The maximum of cumulative number is two, and the maximum single dose does not exceed 800mg."
            }
        ],
        "intervention": [
            {
                "intervention_type": "Drug",
                "intervention_name": "Favipiravir Combined With Tocilizumab",
                "description": "Favipiravir: On the 1st day, 1600mg each time, twice a day; from the 2nd to the 7th day, 600mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days.\nTocilizumab:The first dose is 4 ~ 8mg/kg and the recommended dose is 400mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hours after the first dose and the interval between two medications \u2265 12 hours.Intravenous infusion, The maximum of cumulative number is two, and the maximum single dose does not exceed 800mg.",
                "arm_group_label": "Favipiravir Combined With Tocilizumab group"
            },
            {
                "intervention_type": "Drug",
                "intervention_name": "Favipiravir",
                "description": "On the 1st day, 1600mg each time, twice a day; from the 2nd to the 7th day, 600mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days.",
                "arm_group_label": "Favipiravir group"
            },
            {
                "intervention_type": "Drug",
                "intervention_name": "Tocilizumab",
                "description": "The first dose is 4 ~ 8mg/kg and the recommended dose is 400mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hours after the first dose and the interval between two medications \u2265 12 hours.Intravenous infusion, The maximum of cumulative number is two, and the maximum single dose does not exceed 800mg.",
                "arm_group_label": "Tocilizumab group"
            }
        ],
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Clinically diagnosed with Corona Virus Disease 2019\n\n          2. Increased interleukin-6\n\n          3. Sign the informed consent\n\n          4. Subjects who can take medicine orally\n\n          5. Agree to collect clinical samples\n\n          6. Female subjects of childbearing age are not pregnant and agree to take effective\n             contraception within 7 days of the last oral medication to ensure that they are not\n             pregnant within 3-6 months\n\n          7. Male patients agree to effective contraception within 7 days of last oral medication.\n\n        Exclusion Criteria:\n\n          1. Cases of severe vomiting that make it difficult to take the drug orally\n\n          2. Allergic to Favipiravir or tocilizumab\n\n          3. Pregnant and lactating women\n\n          4. Subjects received specific antiviral drugs such as lopinavir / ritonavir, ribavirin,\n             arbidol, chloroquine phosphate, hydroxychloroquine, and monoclonal antibodies within\n             one week before admission.\n\n          5. Cases of respiratory failure and requiring mechanical ventilation\n\n          6. Cases of shock\n\n          7. Combined organ failure requires ICU monitoring and treatment\n\n          8. Predicted clinically that there is no hope of survival, or cases of deep coma that do\n             not respond to supportive treatment measures within three hours of admission\n\n          9. Alanine aminotransferase / Aspartate aminotransferase> 5 times of upper limit of\n             normal\n\n         10. Neutrophils <0.5 \u00d7 10^9 / L, platelets less than 50 \u00d7 10^9 / L\n\n         11. Clear diagnosis of rheumatoid immunity, malignant tumors and other related diseases\n\n         12. Long-term oral anti-rejection drugs or immunomodulatory drugs\n\n         13. Allergic reactions to tocilizumab or any excipients\n\n         14. Patients with active hepatitis, tuberculosis, and definite bacterial and fungal\n             infections\n\n         15. Organ transplant patients\n\n         16. Patients with mental disorders"
            },
            "gender": "All",
            "minimum_age": "18 Years",
            "maximum_age": "65 Years",
            "healthy_volunteers": "No"
        },
        "overall_official": {
            "last_name": "Guiqiang Wang",
            "role": "Principal Investigator",
            "affiliation": "Peking University First Hospital"
        },
        "overall_contact": {
            "last_name": "Guiqiang Wang",
            "phone": "13911405123",
            "email": "john131212@sina.com"
        },
        "overall_contact_backup": {
            "last_name": "Hong Zhao",
            "phone": "13810765943",
            "email": "zhaohong_pufh@bjmu.edu.cn"
        },
        "location": [
            {
                "facility": {
                    "name": "Guiqiang Wang",
                    "address": {
                        "city": "Beijing",
                        "state": "Beijing",
                        "zip": "100034",
                        "country": "China"
                    }
                },
                "status": "Recruiting",
                "contact": {
                    "last_name": "Guiqiang Wang",
                    "phone": "13911405123",
                    "email": "john131212@sina.com"
                }
            },
            {
                "facility": {
                    "name": "Peking University First Hospital",
                    "address": {
                        "city": "Beijing",
                        "state": "Beijing",
                        "zip": "100034",
                        "country": "China"
                    }
                },
                "status": "Recruiting",
                "contact": {
                    "last_name": "Haichao Li",
                    "phone": "18511129044"
                }
            },
            {
                "facility": {
                    "name": "Ezhou Central Hospital",
                    "address": {
                        "city": "Wuhan",
                        "state": "Hubei",
                        "zip": "430000",
                        "country": "China"
                    }
                },
                "status": "Recruiting",
                "contact": {
                    "last_name": "Yuhong Qin",
                    "phone": "13810634388"
                }
            },
            {
                "facility": {
                    "name": "Huoshenshan Hospital of Wuhan",
                    "address": {
                        "city": "Wuhan",
                        "state": "Hubei",
                        "zip": "430000",
                        "country": "China"
                    }
                },
                "status": "Recruiting",
                "contact": {
                    "last_name": "Qing Mao"
                }
            },
            {
                "facility": {
                    "name": "Jinyintan Hospital of Wuhan",
                    "address": {
                        "city": "Wuhan",
                        "state": "Hubei",
                        "zip": "430000",
                        "country": "China"
                    }
                },
                "status": "Recruiting",
                "contact": {
                    "last_name": "Dingyu Zhang",
                    "phone": "13507117929"
                }
            },
            {
                "facility": {
                    "name": "Wuhan Pulmonary Hospital",
                    "address": {
                        "city": "Wuhan",
                        "state": "Hubei",
                        "zip": "430000",
                        "country": "China"
                    }
                },
                "status": "Recruiting",
                "contact": {
                    "last_name": "Xianxiang Chen",
                    "phone": "18971570937"
                }
            }
        ],
        "location_countries": {
            "country": "China"
        },
        "verification_date": "April 2020",
        "study_first_submitted": "March 9, 2020",
        "study_first_submitted_qc": "March 14, 2020",
        "study_first_posted": {
            "@type": "Actual",
            "#text": "March 17, 2020"
        },
        "last_update_submitted": "April 8, 2020",
        "last_update_submitted_qc": "April 8, 2020",
        "last_update_posted": {
            "@type": "Actual",
            "#text": "April 10, 2020"
        },
        "responsible_party": {
            "responsible_party_type": "Principal Investigator",
            "investigator_affiliation": "Peking University First Hospital",
            "investigator_full_name": "Guiqiang Wang",
            "investigator_title": "Principal Investigator"
        },
        "keyword": [
            "Novel coronavirus pneumonia",
            "Favipiravir",
            "Tocilizumab"
        ],
        "condition_browse": {
            "mesh_term": "Virus Diseases"
        }
    }
}